Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Exenatide treatment improves glycemia in adults with type 2 diabetes and has been shown to reduce postprandial hyperglycemia in adolescents with type 1 diabetes. We studied the effects of exenatide on glucose homeostasis in adults with long-standing type 1 diabetes. RESEARCH DESIGN AND METHODS: Fourteen patients with type 1 diabetes participated in a crossover study of 6 months' duration on exenatide (10 μg four times a day) and 6 months off exenatide. We assessed changes in fasting and postprandial blood glucose and changes in insulin sensitivity before and after each study period. RESULTS: High-dose exenatide therapy reduced postprandial blood glucose but was associated with higher fasting glucose concentrations without net changes in hemoglobin A1c. Exenatide increased insulin sensitivity beyond the effects expected as a result of weight reduction. CONCLUSIONS: Exenatide is a promising adjunctive agent to insulin therapy because of its beneficial effects on postprandial blood glucose and insulin sensitivity in patients with type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While several studies included in their analysis did not find significant changes in HbA1c, they did find a reduction in insulin requirements.15,35,36”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Muniyappa, R., Lee, S., Chen, H., & Quon, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00645.2007 · Cited by 1,643 · cited 1×
“Herein, we report the effects of 6 months of therapy with exenatide in patients with long-standing type 1 diabetes focusing on outcomes related to glucose homeostasis, including fasting and postprandial blood glucose and insulin sensitivity, as determined by the reference glucose clamp method (4).”
MethodSelf-citationPostprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945 · cited 1×
“Postprandial glucose has emerged as a strong predictor of cardiovascular risk compared with fasting glucose (6).”
Backgroundα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Gedulin, B. R., Nikoulina, S. E., Smith, P. A., Gedulin, G., Nielsen, L. L., Baron, A. D., Parkes, D. G., & Young, A. A. (2005) · Endocrinology · doi:10.1210/en.2004-1349 · Cited by 242
Schauer, I. E., Snell-Bergeon, J. K., Bergman, B. C., Maahs, D. M., Kretowski, A., Eckel, R. H., & Rewers, M. (2011) · Diabetes · doi:10.2337/db10-0328 · Cited by 230
Rother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Self-citationExendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes
Dupré, J., Behme, M. T., & McDonald, T. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032001 · Cited by 133
Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes
Bergman, B. C., Howard, D., Schauer, I. E., Maahs, D. M., Snell-Bergeon, J. K., Eckel, R. H., Perreault, L., & Rewers, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3172 · Cited by 107
Cited by
Obesity, insulin resistance, and type 1 diabetes mellitus
Polsky, S., & Ellis, S. L. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000170 · Cited by 235
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“15,35,36 Furthermore, differences in hypo-glycemic events were not substantial or reduced in combination treatment, suggesting that combination treatment does not increase the risk of hypoglycemia.”
BackgroundCombination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor
DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12982 · Cited by 192
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Dejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Metadata
- Authors
- Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I.
- Affiliations
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- UMass Memorial Health Care (US)
- Corresponding author
- Rother, Kristina I.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-02-11
- Volume
- 37
- Issue
- 3
- Pages
- 666-670
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3931382
- OpenAlex
- W2152918233
- Cited by
- 74
- References
- 14
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 1 · 2018: 6 · 2017: 11 · 2016: 14 · 2015: 14 · 2014: 6
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079637)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- exenatide, type 1 diabetes, insulin sensitivity, postprandial blood glucose, fasting blood glucose, glucose homeostasis, GLP-1 receptor agonists, weight loss
- MeSH terms
- Exenatide, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Drug Administration Schedule, Fasting, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Male, Middle Aged, Peptides, Venoms, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc13-1473
- The paper
- Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014). Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc13-1473
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.